Clinical Trial: To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer

U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07370818) titled 'To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer' on Jan. 12.

Brief Summary: This study aims to to evaluate the efficacy, safety, and pharmacokinetics of JPI- 547 with bevacizumab maintenance therapy in relapsed ovarian cancer patients

Study Start Date: Feb. 27

Study Type: INTERVENTIONAL

Condition: Ovarian Cancer

Intervention: DRUG: JPI-547

taking JPI-547

DRUG: Bevacizumab

administration Bevacizumab

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Onconic Therapeutics Inc.

Disclaimer: Curated by HT Syndication....